Origin Pharma has designed a creative solution for the pharmaceutical industry supply chain, the Hybrid Pharma Packaging Partner (HP3).
This innovative model aims to improve efficiency and drive profits. HP3 is born into the modern Pharmaceutical market, where competition is accelerating due to scientific and technological innovations both within and outside the sector. It’s born into a client pool concerned to remain relevant and increase momentum, whilst ensuring that attributes critical to the successful delivery of health and well-being remain intact. It’s born into the only market where speed and perfection are fundamental to success.
Hybrid Pharma Packaging Partner (HP³) is a change programme designed to accelerate the competitiveness of the pharmaceutical primary packaging industry by raising the performance of its supply chains. International competition, together with the challenges posed by government legislation, necessitates rapid improvement in the effectiveness of the industry’s supply chain.
Keith Wade of Origin explains why HP3 is becoming a critical aspect of the top 25 pharmaceutical companies’ supply chains. He says: "Since 2010, we’ve been developing a supply chain solution alongside key stakeholders in the top 10.
"The presence of disruptive improvements to the value chain in bordering markets lead us to challenge the constraints within the pharmaceutical market we serve. Historically, speed to market was not considered to be negotiable, in fact statistics show it takes an average of 10 years to bring a new drug product to the market.
"We border Electronics (an industry category with a comparable spend in R&D) where it takes an average of 12 weeks to develop a new app. HP3 facilitates the evolving migration of certain factors across to our industry."
Wade goes on to describe and compare why HP3 will drive efficiency and improve profits, saying: "Our clients realise that the effectiveness of the supply chain in for example the Aerospace industry is an essential attainment in order to remain competitive. Although diverse, both examples reference some essential processes applicable to all markets.
"A new drug product won’t be developed in 12 weeks, but applying effective methodology combining speed, leadership, and flexibility minimises the development time and cost to bring your brand safely to market."
HP3 compiles three facets of the pharmaceutical primary packaging function, design and development, strategic manufacturing and supply chain consolidation. These give the client the ability to use the HP3 full process from concept to fulfilment or utilise the aspects applicable to their current requirements.
For example, Origin Pharma assist large pharma companies with their supply chain by consolidating both suppliers and processes (sourcing raw materials and streamlining transport) to reduce cost, improve profitability, and drive efficiency.
Through the securing of dedicated manufacturing and storage facilities in strategic locations across multiple countries, we remain within a short distance of our clients’ bases of operation. HP3 also removes manufacturing constraints and allows unlimited access to approved production sites, which encompass all manufacturing techniques. So, no matter what the job, we can deliver to precise specifications and a strict deadline.
Hybrid Pharma Packaging Partner is a new model, which respects the critical nature of quality control, regulatory compliance and change management, yet alleviates traditional constraints. It is born of the frustrations of industry stakeholders wanting to pioneer improvements from speed to market to a streamlined supply chain.
HP3 is stimulating the pharmaceutical market, galvanising developments within the top 10 and will is a guaranteed challenger to the ‘norm’.